Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

Main Who May Qualify: - Patients with AML, ALL or MDS eligible for an allogeneic HSCT with a haploidentical donor with post-transplant cyclophosphamide. - Patients must be ≥ 18 years of age at the time of signing the ICF. - Patients must have a Karnofsky index ≥ 70%. - Patients must have a left ventricular ejection fraction of ≥40%. - Patients must have an intact pulmonary function or Diffusing capacity of the Lungs for Carbon Monoxide (DLCO) ≥ 45% of predicted. - Patients must have adequate hepatic and renal functions, as assessed by standard laboratory criteria. Main Who Should NOT Join This Trial: - Patients who have received prior allogeneic stem cell transplantation. - Patients who have received prior treatment with another cellular therapy within 4 weeks before the planned day of SMART101 infusion. - Patients who plan to receive, are concurrently receiving or have received any investigational agent within 4 weeks before the planned day of SMART101 infusion. Always talk to your doctor about whether this trial is right for you.